Semua Penyebab Kematian Dalam Kaitannya Dengan Hemoglobin Terglikasi Pada Individu Dengan Diabetes...
3
The question ( PICO ) of the study • P ( Population/problem) : Clinical-pathologic variables in patients with a new diagnosis of hepatocellularcarcinoma (HCC) and underlying hepatitis B vs. C infection • I ( Intervention ) : No intervention • C ( Compare ) : Evaluate potentially significant clinical-pathologic differences in HCC’s that develop in association with chronic HBV vs.HCV • O (Outcome ) : Significant clinical-pathologic differences exist and impact eligibility for potentially-curative therapy and prognosis among HCC patients with underlying HBV vs. HCV. Critical Appraisal Evidence Based Medicine Prognostic Aspect I.Are the results of this prognosis study valid? 1. The study addresses an appropriate and clearly focused question? Yes, 2. Was patient follow up sufficiently long and complete? Yes, the patients were follow up sufficiently long and complete 3. Were objective outcome criteria aplied in a blind fashion? No, this research use double blind method 4. If subgroup with defined prognoses are identified was there adjusment for important prognostic factors? No sub group in this study 5. Was there validation in a independent group of patients?
-
Upload
donkeyendut -
Category
Documents
-
view
218 -
download
0
description
Semua Penyebab Kematian Dalam Kaitannya Dengan Hemoglobin Terglikasi Pada Individu Dengan Diabetes Tipe 2
Transcript of Semua Penyebab Kematian Dalam Kaitannya Dengan Hemoglobin Terglikasi Pada Individu Dengan Diabetes...
The question ( PICO ) of the study
• P ( Population/problem) :
Clinical-pathologic variables in patients with a new diagnosis of hepatocellularcarcinoma (HCC) and underlying hepatitis B vs. C infection
• I ( Intervention ) :
No intervention
• C ( Compare ) :
Evaluate potentially significant clinical-pathologic differences in HCC’s that develop in association with chronic HBV vs.HCV
• O (Outcome ) :
Significant clinical-pathologic differences exist and impact eligibility for potentially-curative therapy and prognosis among HCC patients with underlying HBV vs. HCV.
Critical Appraisal Evidence Based Medicine Prognostic Aspect
I.Are the results of this prognosis study valid? 1. The study addresses an appropriate and clearly focused question?
Yes, 2. Was patient follow up sufficiently long and complete?
Yes, the patients were follow up sufficiently long and complete 3. Were objective outcome criteria aplied in a blind fashion?
No, this research use double blind method4. If subgroup with defined prognoses are identified was there adjusment for important prognostic factors?
No sub group in this study 5. Was there validation in a independent group of patients?
No independent group in this study
Clinical Measurement SE CI Calculation
Proportion : Number of pat = n Patient proportion of outcome = p
√ {p x (1-p)/n} If p = 9721/110.372=0,09 =(or 9%) n = 110.372 SE = √ ( 0,09 x( 1 – 0,09) / 110.372 = 0,0009 = 0,09% 95% CI = 9% ± 1,96 x 0,09% = 9 % ± 0,18% = 8,82 % - 9,18%
n = 110.372 p = 9721/110.372=0,09
Calculation : SE : 0,09% CI 95 % : 8,82 % - 9,18%
II. Are the valid results of prognosis study important? 1.How likely are the outcomes over time?
n = 110.372 p = 9721/110.372=0,09 SE : 0,09 %
2.How precise are the prognostic estimates? CI 95 % = 8,82 % - 9,18%
III. Can we applied the evidence of these valid and important prognostic aspect to our patients?
Does patient on this study look like our patient? Yes
Does evidence will have important Influence clinically toward our conclusion about what we should offer or tell to our patients?
Yes
